Open AccessEffektivnost' primeneniya preparata«Magnerot®» pri proyavleniyakh sindromasosudistykh narusheniy i gemorragicheskogosindroma u bol'nykh s idiopaticheskimprolapsom mitral'nogo klapana
Author(s) -
Е В Акатова,
Акатова Евгения Владимировна,
О П Николин,
Николин Олеся Петровна,
А.И. Мартынов,
Мартынов Анатолий Иванович
Publication year - 2011
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs44956
Subject(s) - medicine , placebo , incidence (geometry) , gastroenterology , mitral valve prolapse , surgery , mitral valve , pathology , physics , alternative medicine , optics
Summary. Aim. To evaluate the efficiency of placebo-controlled magnerot use on vascular and hemorrhagic manifestationsin patients with idiopathic mitral valve prolapse (MVP).Subjects and methods. Seventy-four patients (31,7% males and 68,3% women) with idiopathic MVP were examinedduring a single-blind placebo-controlled study. They were randomized into 2 groups: 1) magnerot (a study group)and 2) placebo (a control group). The mean age of the study group patients was 30,80,4 years. The placebo groupwas matched by age (mean age 31,10,2) and gender. There was a female preponderance among the examinees inboth groups. The study group patients received MagnerotR tablets containing 500 mg of Mg orotate (32,8 Mg of elementaryMg) in a daily dose of 3000 mg (196,8 mg of elementary Mg) for 6 months. All the patients underwentcomprehensive examination before and 6 months after the study.Results. A clinical significant reduction in the degree of vascular disorders was noted in 71,3% of the patients with MVP.The incidence of vascular disorders remained virtually unchanged in the study group. Vascular disorders were significantlyalleviated after the therapy. If before the therapy, mild, moderate, and severe vascular disorders were diagnosedin 30,2, 55,9, and 13,9% of cases, respectively; whereas after the therapy these were absent in 16,3% of cases; the patientswith mild vascular disorders increased by 2,5-fold and their severe form was undetected. The clinical effect ofthe therapy on the severity of hemorrhagic syndrome was observed in 81,4% of patients (75% males and 89,5% females)and the therapeutic efficiency that very frequently corresponded to clinical improvement was seen in 2,3%.Conclusion. The effect of magnerot therapy is shown to significantly reduce the incidence and degree of vasculardisorders and hemorrhagic syndrome and their clinical picture as a whole.